ArticleCell2006
Targeting of aberrant mRNAs to cytoplasmic processing bodies.
Article in Cell, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
163 citing papers in PubMed.
- Epistatic impacts of cis- and trans-regulatory mutations on the distribution of mutational effects for gene expression in Saccharomyces cerevisiae.Molecular biology and evolution · 2026Article
- SMG7 and eIF4A constitute a homeostatic module controlling P-body condensation and function of meiotic bodies.Nature communications · 2026Article
- Imaging Techniques for the Study of Protein Condensates and Filaments and Their Applications.International journal of molecular sciences · 2026Review
- Plant P-bodies in post-transcriptional control: Composition, dynamics, and context-dependent roles.Plant communications · 2026Review
- UPF1 shuttles between nucleus and cytoplasm independently of its RNA-binding and ATPase activities.RNA (New York, N.Y.) · 2025Article
- Current perspectives in drug targeting intrinsically disordered proteins and biomolecular condensates.BMC biology · 2025Review
- Recent Advances in the miRNA-Mediated Regulation of Neuronal Differentiation and Death.Neuromolecular medicine · 2024Review
- UPF1 regulates mRNA stability by sensing poorly translated coding sequences.Cell reports · 2024Article
- Eukaryotic mRNA decapping factors: molecular mechanisms and activity.The FEBS journal · 2023Review
- The RNA helicases Dbp2 and Mtr4 regulate the expression of Xrn1-sensitive long non-coding RNAs in yeast.Frontiers in RNA research · 2023Article
- Nonsense-mediated mRNA decay uses complementary mechanisms to suppress mRNA and protein accumulation.Life science alliance · 2022Article
- Determinants of the temperature adaptation of mRNA degradation.Nucleic acids research · 2022Article
- Ribosome dynamics and mRNA turnover, a complex relationship under constant cellular scrutiny.Wiley interdisciplinary reviews. RNA · 2021Review
- CTP synthase is essential for early endosperm development by regulating nuclei spacing.Plant biotechnology journal · 2021Article
- Regulation of nonsense-mediated mRNA decay in neural development and disease.Journal of molecular cell biology · 2021Review
- Smart-ORF: a single-molecule method for accessing ribosome dynamics in both upstream and main open reading frames.Nucleic acids research · 2021Article
- Stress Granule-Mediated Oxidized RNA Decay in P-Body: Hypothetical Role of ADAR1, Tudor-SN, and STAU1.Frontiers in molecular biosciences · 2021Article
- A quantitative inventory of yeast P body proteins reveals principles of composition and specificity.eLife · 2020Article
- RPS28B mRNA acts as a scaffold promoting cis-translational interaction of proteins driving P-body assembly.Nucleic acids research · 2020Article
- Article
103 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
In eukaryotes, a specialized pathway of mRNA degradation termed nonsense-mediated decay (NMD) functions in mRNA quality control by recognizing and degrading mRNAs with aberrant termination codons. We demonstrate that NMD in yeast targets premature termination codon (PTC)-containing mRNA to P-bodies. Upf1p is sufficient for targeting mRNAs to P-bodies, whereas Upf2p and Upf3p act, at least in part, downstream of P-body targeting to trigger decapping. The ATPase activity of Upf1p is required for NMD after the targeting of mRNAs to P-bodies. Moreover, Upf1p can target normal mRNAs to P-bodies but not promote their degradation. These observations lead us to propose a new model for NMD wherein two successive steps are used to distinguish normal and aberrant mRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.